Modified clostridial neurotoxins with altered biological persistence
CA 2428136 A1 · Owner: Aoki, Kei Roger · Inventors: Steward, Lance E.; Spanoyannis, Athena; Aoki, Kei Roger
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins and the modification involves one or more secondary modification sites. In a BoNT/E (Botilunum Toxin serotype E) derivative, the N-terminal myristylation site GVDIAY is fused to position 15 of the BoNT/E light chain. In a BoNT/A derivative the N-terminal myristylation site GLEVSF at position 254 is deleted. Such modified neurotoxins may be employed in treating various conditions including but not limited to muscular disorders, hiperhidrosis, and pain.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 16, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 16, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 16, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.